Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Recent Posts
- Government shutdown: House to vote on last-minute funding bill without debt limit hike
- The Fed cut interest rates, but mortgage costs jumped. Here’s why
- As Congress works to avoid a shutdown, here’s what’s next for a bill to increase Social Security benefits for public pensioners
- Number of millennial 401(k) millionaires jumps 400%: Here’s what it takes to reach seven-figure status
- Banking app Dave, back from the brink, is this year’s biggest gainer among financials with 934% surge